Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer’s Asia Pacific Regional Head Chris Lee On Bayer’s New Global R&D Center In Beijing And China’s Rising 21st Century Importance: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Bayer Schering Pharma Asia Pacific's Regional Head Chris Lee recently discussed with PharmAsia News' China Bureau Bayer's plans to create a new €100 million research and development center in Beijing and China's strengthening role in the company's 21st century blueprints for expansion. Bayer Schering's first global R&D center in Asia is slated to be operational by 2010, and will be the third in a triumvirate of research outposts that Bayer oversees worldwide (PharmAsia News, Feb. 19, 2009).

You may also be interested in...



Bayer's Betaferon Approved In China; Launch Likely In Mid 2010

SHANGHAI - Germany-based Bayer Schering Pharma announced Dec. 1 that China's State FDA approved its multiple sclerosis treatment Betaferon/Betaseron (interferon beta-1b). Bayer plans to launch the drug by mid-2010

Bayer's Betaferon Approved In China; Launch Likely In Mid 2010

SHANGHAI - Germany-based Bayer Schering Pharma announced Dec. 1 that China's State FDA approved its multiple sclerosis treatment Betaferon/Betaseron (interferon beta-1b). Bayer plans to launch the drug by mid-2010

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

BEIJING - The heads of Germany's Bayer Schering Pharma AG and the Polish biotech firm Bioton, which produces human recombinant insulin, met in the Chinese capital this week to sign an agreement that sets the stage for Bayer to market the biopharmaceutical SciLin across China

Related Content

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel